Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1)

Estour, Bruno; Herle, André J. Van; Juillard, G; Totanes, T. L.; Sparkes, Robert S.; Giuliano, Armando E.; Klandorf, H.

doi:10.1007/bf02899078

Cited by 92 publications

(63 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among TTFs, PAX8 was found in FTC133, WRO82-1, BCPAP, and TPC1 cells, TTF-1 was expressed in all the cell lines and TTF-2 was faintly detected in WRO82-1, TPC1, and BCPAP cell lines. Their inability to detect TSH-R expression in all the cell lines differed from previous studies by other investigators (20)(21)(22)(23)(24)(25). One can attribute the above discrepancies to different experimental conditions such as varying numbers of polymerase chain reaction cycles used and=or different durations of exposure of immunoblots (25).…”

Section: Papillary Thyroid Cancercontrasting

confidence: 65%

See 1 more Smart Citation

Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer

Pilli

Prasad

Jayarama

et al. 2009

Thyroid

View full text Add to dashboard Cite

Section: Papillary Thyroid Cancercontrasting

confidence: 65%

“…An extensive karyotype description has been reported only for the FTC133 and WRO82-1 cell lines (12,21,28). In particular, the FTC133 cells revealed significant gains in part or whole of chromosomes 1,11,6,7,8,14,15,19, and 20, and losses in chromosomes 16, 21, and 22 (28).…”

Section: Ftcmentioning

confidence: 99%

Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer

Pilli

Prasad

Jayarama

et al. 2009

Thyroid

View full text Add to dashboard Cite

“…To study the biology of bone metastasis in FTC, we used the well-established human FTC cell line WRO (32). To assess the levels of the EGFR family of receptors in human thyroid cancer, we used the following cell lines: ARO, DRO, K18, K4, C643, Hth74 (anaplastic thyroid carcinoma), and NPA187 (papillary thyroid cancer).…”

Section: Methodsmentioning

confidence: 99%

Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation

Younes¹,

Yigitbasi²,

Park³

et al. 2005

Cancer Research

View full text Add to dashboard Cite

Patients suffering from bone metastases of follicular thyroid carcinoma (FTC) have a poor prognosis because of the lack of effective treatment strategies. The overexpression of epidermal growth factor receptor (EGFR) associated with increased vascularity has been implicated in the pathogenesis of FTC and subsequent bone metastases. We hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure. We tested this hypothesis using the human WRO FTC cell line. In culture, AEE788 inhibited the EGF-mediated phosphorylation of EGFR, VEGFR2, mitogen-activated protein kinase, and Akt in culture. AEE788, alone and in combination with paclitaxel, inhibited cell growth and induced apoptosis. When WRO cells were injected into the tibia of nude mice, tumor and endothelial cells within the lesions expressed phosphorylated EGFR, VEGFR, Akt, and mitogenactivated protein kinase that were inhibited by the oral administration of AEE788. Therapy consisting of orally given AEE788 and i.p. injected paclitaxel induced a high level of apoptosis in tumor-associated endothelial cells and tumor cells with the inhibition of tumor growth in the bone and the preservation of bone structure. Collectively, these data show that blocking the phosphorylation of EGFR and VEGFR with AEE788 combined with paclitaxel can significantly inhibit experimental human FTC in the bone of nude mice. (Cancer Res 2005; 65(11): 4716-27)

show abstract

“…Human anaplastic thyroid cancer cell lines SW1736 and C643 (Mark et al, 1987) were kindly provided by Dr NE Heldin, Denmark, and human follicular thyroid cancer cell lines ML1 (Schonberger et al, 2000) and WRO (Estour et al, 1989) were from J Schonberger. The human papillary thyroid cancer cell line NPA was a gift from Professor Santoro, Italy (Fagin et al, 1993).…”

Section: Cellsmentioning

confidence: 99%

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO

Rebuffat¹,

Morin²,

Nguyen³

et al. 2010

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Thyroid cancers are difficult to treat due to their limited responsiveness to chemo-and radiotherapy. There is thus a great interest in and a need for alternative therapeutic approaches. RESULTS: We studied the cytotoxic activity of anti-thyroperoxidase autoantibodies (anti-TPO aAbs, expressed in baculovirus/insect cell (B4) and CHO cells (B4 0 ) or purified from patients' sera) against a papillary thyroid cancer (NPA) cell line. Anti-TPO aAbs from patients' sera led to a partial destruction of NPA cell line by complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) and exhibited an anti-proliferative activity. Comparison of the cytotoxic activity of anti-TPO aAbs shows that B4 0 induced an anti-proliferative effect and a better ADCC than B4, but a lower one than anti-TPO aAbs from patients' sera. Antibody-dependent cell-mediated cytotoxicity was increased when human peripheral blood mononuclear cells were used as effector cells, suggesting that FcgRs, CD64, CD32 and CD16 are involved. Indeed, anti-TPO aAbs from patients' sera, but not B4 and B4 0 , exhibited CDC activity. CONCLUSIONS: These data indicate that anti-TPO aAbs display moderate ADCC and anti-proliferative activities on NPA cells; IgG glycosylation appears to be important for cytotoxic activity and ADCC efficiency depends on FcgR-bearing cells. Finally, recombinant human anti-TPO aAbs cannot yet be considered as an optimal tool for the development of a novel therapeutic approach for thyroid cancer.

show abstract

Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1)

Cited by 92 publications

References 16 publications

Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer

Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer

Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO

Contact Info

Product

Resources

About